Document is current

Article History

Received: 18 February 2021

Accepted: 15 April 2021

First Online: 5 May 2021

Declarations

:

: This study is compliant with the Health Insurance Portability and Accountability Act, was approved by the MSK Institutional Review Board, and was conducted per the Declaration of Helsinki ethical principles.

: All of the authors have read and approved the manuscript and possible conflict of interests are disclosed.

: C.B., S.K., S.P., and T.R. are shareholders of Summit Biomedical Imaging, LLC. S.K., S.P., and T.R. are co-inventors on PCT application WO2016164771. T.R. is co-inventor on PCT application WO2012074840. T.R. is a paid consultant for Theragnostics, Inc. All the other authors have no relevant conflict to declare. This arrangement has been reviewed and approved by Memorial Sloan Kettering Cancer Center in accordance with its conflict of interest policies.

: Is the topical application of PARPi-FL safe? Can a mouthwash of the imaging agent provide a level of optical contrast (tumor to margin ratio) apparent to the human observer?

: Topical application of PARPi-FL is safe and generated contrast-ratios above 3. A benign lesion did not take up the agent, and an undiagnosed contralateral small tumor was identified. PARPi-FL generates mesoscopic contrast by emitting a signal from its nuclear target on a subcellular level.

: PARPi-FL is a simple, in vivo, non-invasive, cost-effective, molecularly specific, fluorescent contrast-based method to enhance oral cancer diagnosis.